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Accumulating evidence suggests that there are important contributions to coronavirus
disease (COVID-19) from redox imbalance and improperly coordinated iron, which cause
cellular oxidative damage and stress. Cells have developed elaborate redox-dependent
processes to handle and store iron, and their disfunction leads to several serious
diseases. Cellular reductants are important as reactive oxygen species (ROS) scavengers
and to power enzymatic repair mechanisms, but they also may help generate toxic ROS.
These complicated interrelationships are presented in terms of a cellular redox/iron/ROS
triad, including ROS generation both at improperly coordinated iron and enzymatically,
ROS interconvertibility, cellular signaling and damage, and reductant and iron chelator
concentration-dependent effects. This perspective provides the rational necessary
to strongly suggest that COVID-19 disrupts this interdependent triad, producing a
substantial contribution to the ROS load, which causes direct ROS-induced protein and
phospholipid damage, taxes cellular resources and repair mechanisms, and alters cellular
signaling, especially in the more critical acute respiratory distress syndrome (ARDS)
phase of the infection. Specific suggestions for therapeutic interventions using reductants
and chelators that may help treat COVID-19 are discussed.
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INTRODUCTION
Hematological and clinical descriptions of patients with coronavirus disease 2019 (COVID-19)
are beginning to accumulate (Cao et al., 2020; Zhou et al., 2020) and will, in this perspective, be
interpreted and correlated to suggest mechanisms that may in part explain the negative biochemical
and physiological changes that are being induced. There is clear evidence of elevated plasma
ferritin, decreased hemoglobin, and altered erythrocyte distribution and shape in COVID-19 (Zhou
et al., 2020), which together can be interpreted as alteration in iron utilization and handling.
Concurrent are the descriptions of acute respiratory distress syndrome (ARDS), “high altitude
sickness,” increased lactate, and the use of ventilators to supplement oxygenation. Also observed is
greatly elevated C-reactive protein (CRP), implying an inflammatory response that is potentially
linked to reactive oxygen species (ROS) oversignaling and ROS-produced cellular damage. In
COVID-19, there is increased survival associated with higher selenium level and non-elevated
(sufficient) glutathione reductase (Cao et al., 2020), which likely involve appropriate physiological
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scavenging of ROS and repair of ROS-induced oxidative
damage, and can be interpreted as suggestive of cellular
redox involvement. Interestingly, glutathione level declines with
age, and the elderly appear to be hit hardest by COVID-
19. Iron and ROS can cause abnormalities in fibrinogen
cellular behavior (Lipinski and Pretorius, 2012), interpretable as
perhaps associated with the observed thrombosis in COVID-
19. Additionally, ferroptosis, which is a form of cell death that
depends on ROS-centered phospholipid damage and differs from
apoptosis, necrosis, and classical autophagy, can be induced by
glutathione deficiency and excess iron (Lei et al., 2019). Taken
together, these histological and clinical observations in COVID-
19 patients and my above-given interpretations point toward
a redox/iron/ROS triad as potentially deeply involved in acute
COVID-19. Importantly, this triad is strongly interrelated itself
because (1) iron transport, utilization as a cofactor, and storage
are highly dependent on tight control of its redox state; (2)
reductants and iron can be a physiological source of ROS; and
(3) reductants can scavenge ROS (Crichton, 2016).
CELLULAR IRON, REDOX, ROS, DAMAGE,
AND REPAIR
A large number of biochemical macromolecules require specific
iron coordination for their biochemical function (e.g., oxygen
binding and protein-based iron cellular transport). Normally,
∼95% of cellular iron is safely bound to various proteins
(Crichton, 2016). Hemoglobin is the largest iron utilization
protein in the body and, if compromised, can release substantial
iron in hemoglobin-centered disorders. Ferritin is the major iron
storage protein and is noted to act as an “antioxidant” because
it safely sequesters and stores excess iron within its protective
shell in an unreactive form. Normally, only a small portion of
cellular iron becomes part of a liable, non-protein-bound iron
pool (the LIP) and is bound to and carried by molecules such as
citrate (Crichton, 2016). Improperly coordinated iron, especially
in the presence of high oxygen and reductant concentrations
such as in the lung, has the potential to generate ROS such
as hydrogen peroxide, superoxide, and the hydroxyl radical
(Halliwell and Gutteridge, 1985). The details of iron coordination
(i.e., the number and identity of chemical groups bound to
the iron donated by endogenous cellular iron carrier molecules
or clinical chelators) determine whether the iron is properly
coordinated or can produce damaging ROS. In addition to
this toxic generation, ROS are also formed cellularly (1) at
low concentrations for an intricate network of signaling, (2)
for defense against pathogens at higher concentrations [e.g., in
the neutrophils by reduced nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase], and (3) by enzymes misfiring
along normal cycles, although these are expected and generally
appropriately handled by the cellular antioxidant systems in
healthy individuals. Because hydrogen peroxide is important as a
ROS that is active in cellular signaling, excess could be disruptive
(Sies, 2017).
There are ∼30 enzymes from which ROS can originate, and
complicating this further is that both enzymes and improperly
coordinated iron can transform one ROS to another potentially
increasing or decreasing toxicity or terminating them as water.
Superoxide dismutase can convert superoxide to hydrogen
peroxide, and catalase can convert hydrogen peroxide to water
(Banerjee, 2008). Importantly, one form of a family of glutathione
peroxidases can eliminate hydrogen peroxide, and another
(GPX4) can repair ROS-damaged phospholipids. Uncontrollable
ROS-centered damage to phospholipids is considered a main
marker for ferroptosis, and sufficient reduced glutathione level
and available GPX4 are crucial in inhibiting and repairing such
damage (Lei et al., 2019). Unlike catalase, GPX4 requires the
cellular reductant glutathione for enzymatic activity. Glutathione
requires NADPH for conversion from its oxidized form (GSSH)
to its reduced form (GSH) by the enzyme glutathione reductase,
which points to the importance of the availability of the cellular
reductant NADPH and even glucose. NADPH, in turn, is
synthesized by the pentose phosphate (PPP) pathway from
glucose, and general cellular reduction is a marker for metabolic
health. Importantly, erythrocytes depend exclusively on this
pathway for NADPH availability. Lack of appropriate levels of
cellular reductants points toward cellular and oxidative stress and
is a predictor of cell death. A compromised PPP through glucose-
6-phosphate dehydrogenase mutation and the resulting lack of
NADPHproduction, depending on consumption of certain foods
or drugs, can lead to the inability to keep hemoglobin iron
ferrous, hemoglobin destruction, iron release, and erythrocyte
lysing (Fibach and Rachmilewitz, 2017).
More generally, with respect to ROS-induced cellular damage,
the hydroxyl radical causes the greatest by attacking and
modifying biomolecules close to it because of its high reactivity
and thus low diffusibility. Hydrogen peroxide is considered the
least damaging and is able to travel and permeate membranes
and superoxide intermediate. ROS cause oxidative damage to
cellular constituents including protein side chain modification
and polypeptide backbone cleavage, changing their function,
stability, solubility, and aggregation profile. Phospholipids are
also damaged by ROS, not only changing their function and
membrane stability but also producing secondary ROS that go on
to cause further cellular damage. Additionally, repair, disposal,
and new synthesis of unrecoverable proteins and phospholipids
that are initiated by ROS-induced damage are taxing to cells both
materially and energetically (Muhoberac and Vidal, 2019). This
iron-centered ROS damage detracts from other infection-fighting
cellular responses, weakening the cell and disrupting physiology.
CHEMISTRY OF IRON, CHELATORS,
REDUCTANTS, AND ROS
Iron behavior differs substantially from atoms that do not
undergo redox chemistry. Ferrous and ferric iron have different
aqueous solubilities, preferences for coordinating groups, and
reactivities. Binding constants for ferric can be several orders of
magnitude greater than ferrous for the same bound molecule.
Iron coordination alters the ability of iron to be reduced whether
in aqueous solution or in the cell. Furthermore, bound molecules
may transiently dissociate as part of normal chemical equilibrium
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or, more permanently, as composition and concentrations change
(e.g., during disease progression). Ascorbate and GSH can both
coordinate and reduce iron, and these molecules when in the cell
are part of its overall redox balance. Importantly, the interplay
between iron and cellular iron-binding molecules and reductants
in the LIP is perhaps more likely to enhance the production of ROS
under pathological conditions. Finally, the binding of exogenous
iron chelators, as might be used in therapeutic treatment,
must be considered. Chelation is a general term referring to a
single metal-binding molecule that has more than one metal-
binding, coordinating group, and as such, a chelator may also be
endogenous (i.e., citrate, or a drug).
Iron-centered ROS chemistry is generally introduced and
explained by examining the generation of toxic hydroxyl
radicals in terms of the Fenton/Haber Weiss-type reaction,
by considering the reactions in a solution of ferric iron salt
and hydrogen peroxide with no chelating molecules and no
specific reductant added. However, this approach is somewhat
less in parallel biologically with an ROS generating system that
would contain cellular-like iron chelation of some form and a
directly available reductant (Muhoberac and Vidal, 2019). Such
conditions are supplied by Udenfriend’s reagent, which generates
hydroxyl radicals and contains iron, ethylenediaminetetraacetic
acid (EDTA), and ascorbate, such that (1) the iron is subject
to coordination by carboxylates and nitrogen donors from
EDTA, and (2) the available reductant parallels that of
the cell. Interestingly, ascorbate can be replaced by other
cellularly relevant compounds such as thiols as reductants in
the Udenfriend system enhancing hydroxyl radical generation
(Nappi and Vass, 1997). In normal cells, both ascorbate and
GSH concentrations can be quite high—in the millimolar (mM)
range. Additionally, EDTA, because of constraints in its chemical
structure, has an iron coordination site open to improper
coordination by small molecules (e.g., dioxygen or hydrogen
peroxide) for ROS-generating reactions or transformations.
Using clinical chelators, as examples, Desferrioxamine is
a hexadentate binder providing six iron coordination bonds,
whereas Deferiprone (bidentate) can supply a maximum of two
and would thus require a binding ratio of 1:3 iron/Deferiprone to
completely saturate iron in its normal octahedral coordination.
Clearly, the cellular availability of the latter needs to be higher
for complete iron binding saturation, which turns out to be very
important. If less, iron would be open to interact directly with
small molecules and perhaps a reductant like ascorbate. This
situation, which can be considered improperly coordinated iron,
is dangerous in that it allows generation of or conversion between
ROS, as mentioned earlier. Studies show that bound hexadentate
Desferrioxamine is not likely to generate ROS, but Deferiprone
can do so at low concentrations in that hydroxyl radicals from
Deferiprone are formed at 1:1 and 1:2 solution ratios but are
greatly attenuated at a higher ratio (Devanur et al., 2008).
Furthermore, there may exist competition between the clinical
chelator and available cellular binding molecules potentially
leading to mixed iron coordination and making predictability
difficult. Excess iron removal is clearly important, but choosing the
proper clinical chelator and concentration that does not increase
ROS production is a more important consideration.
Important contributions to the complexity of iron behavior
in cells are the variety and concentration of endogenous iron
binding molecules normally found in the LIP. These include
both redox active and non-active molecules. Generally, citrate
and glutathione are mentioned as the most likely endogenous
iron binders; however, the cellular milieu has many others with
appropriate groups for iron coordination (e.g., lactate, phosphate,
and ascorbate). Both GSH and ascorbate can reduce iron and
enhance hydroxyl radical production in vitro, which leads to
a curious situation. How can these two reductants, which are
well-known as “antioxidants,” have a dual role of producing
damaging ROS? It turns out that both reductants have pro-
and antioxidant ability. In the Udenfriend system of hydroxyl
radical generation, low concentration of ascorbate enhances
hydroxyl radical production through reducing the iron, but
at higher concentration, ascorbate has the ability to scavenge
the radicals it helps produce (Miller and Aust, 1989; Griffiths
and Lunec, 2001). Similarly, GSH can enhance production of
these radicals at lower concentration but apparently scavenges
them as GSH concentration is increased. Although these higher
ascorbate and GSH concentrations for ROS scavenging are not
unrealistic physiologically, they reduce with age and disease.
This dual role points toward the need for maintaining (1) high
physiological concentrations of reductants and their regeneration
(re-reducing) systems for clinical efficacy and (2) availability of
synthesis precursors (e.g., cysteine for GSH). Furthermore, this
concentration dependence for efficacy recalls the debate on utility
of ascorbic acid to treat a variety of conditions (e.g., sepsis, where
a high ascorbate concentration may be the determining factor).
In addition, the ascorbate and GSH cellular pools are linked
through their interconversion and through NADPH-dependent
regeneration producing GSH from its oxidized counterpart,
GSSH, as mentioned earlier. A different kind of dual behavior is
found with some clinical chelators. Desferrioxamine is capable of
scavenging hydroxyl radicals in an efficient manner, increasing
with additional chelator concentration (Kayyali et al., 1998). This
ability is independent of iron and only refers to the trapping
of radicals by the molecular structure of Desferrioxamine itself.
Deferiprone appears to be less capable of such direct trapping.
Thus, in addition to the ability of a chelator to properly
coordinate iron (i.e., bind and shield iron from dioxygen or ROS
interaction), the intrinsic ability of a chelator to scavenge radicals
may be important to consider. In fact, this may eventually be
designed into the chelator, or perhaps, ROS scavengers could be
administered separately.
PATHWAYS OF ROS DAMAGE TO
PROTEINS, LIPIDS, AND CELLS
Examining the triad of depressed cellular redox, elevated iron,
and ROS-induced damage, what are the potential mechanisms
that may contribute to COVID-19? First, pulmonary cells
are particularly susceptible to oxidative stress under normal
conditions, and both their epithelial lining and lavage normally
show high concentrations of the antioxidants GSH and ascorbate.
Under ARDS, both total and non-heme iron are increased,
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markers for ROS-induced damage of proteins and lipids are
found, and there are decreases in ascorbate and GSH (Chabot
et al., 1998). Second, there are well-known, non-COVID-
19, potentially life-threatening hemoglobin-related conditions
associated with elevated iron and enhanced cellular oxidative
damage and stress. Hemoglobin must contain iron-porphyrin
(heme) in the ferrous state for oxygen binding and transport,
even though hemoglobin normally undergoes spontaneous
oxidation at a few percent a day, releasing damaging superoxide
radicals. An uncompromised erythrocyte can deal appropriately
with this through phospholipid repair enzymes and direct
ROS scavenging by GSH, and through a NADPH-dependent
enzyme, methemoglobin reductase, which re-reduces the iron
(Fibach and Rachmilewitz, 2017). Still, ferric iron in and ROS
damage to hemoglobin contribute to Heinz body formation
and cellular lysing, and heme released from hemoglobin can
produce ROS. Importantly, both GSH regeneration and the
reductase require availability of the reductant NADPH, and with
COVID-19-compromized erythrocytes, this may be problematic
because of cellular damage, overburdened pathways, and lack
of available precursors. Third, a direct thrombolytic condition
may arise from improperly coordinated, excess iron release
and its interaction with fibrinogen. Iron directly interacts
with fibrinogen causing an accelerated form of coagulation
that is not ordered structurally like fibrin and is resistant to
dissociation with sodium dodecyl sulfate (SDS) and proteolysis
(Lipinski and Pretorius, 2012). Fourth, the cell death process
of ferroptosis is directly dependent on iron and ROS in that
iron chelators can halt the process and insufficient GSH levels
accelerate it. Interestingly, one of the markers for ferroptosis
is ROS-induced phospholipid damage as found in ARDS.
In ferroptosis, phospholipids are repaired by the selenium-
containing enzyme GPX4, which requires GSH for its function.
This enzyme-based lipid repair is in addition to the direct
scavenging and elimination of ROS by GSH, if available.
As mentioned earlier, COVID-19 survival has connections to
higher selenium level and non-elevated glutathione reductase,
which suggest sufficient repair enzyme and GSH availability.
Fifth, GSH availability hinders not only ROS damage, which
can lead to direct protein crosslinking, but also crosslinking
by keeping sulfhydrals reduced. Such crosslinking and ROS
damage contribute to protein unfolding and aggregation,
which must be handled by a complex degradation system
further stressing the cells. In addition, aggregated or denatured
protein may produce sites of improper iron coordination-
generating ROS. Finally, even the structure and binding
behavior of CRP are altered by ROS modification (Singh et al.,
2017), which may lead to an additional deleterious cascade
of events.
CONCLUSION: ENHANCED REDUCTION
AND CHELATION FOR COVID-19
The redox/iron/ROS triad of COVID-19 is complex and itself
highly interrelated and does not address directly other ongoing
viral-related degrative physiological processes. Such processes
have a number of more standard treatment approaches ranging
from antivirals to immune system modulators. However, the
alteration in cellular redox balance and the need to repair
and eliminate damaged proteins and membranes stemming
from this COVID-19 triad are clearly taxing to the cells and
detrimental to the execution of cellular antiviral defenses,
let alone general metabolism, and these are likely important
components of the overall disease mechanism. The two most
fundamental approaches to therapeutic interventions that would
ameliorate the negative effects of the redox/iron/ROS triad would
be to reduce improperly coordinated iron levels and enhance
reductant levels substantially, particularly in severe COVID-
19 cases.
The purpose of my perspective is not to be prescriptive
but to elicit open mindedness in the exploration of options
for COVID-19 treatment. Clinical iron chelators are available,
and reductants, including ascorbate and GSH, have been
used as IV treatments for a variety of conditions ranging
from septic shock through viral diseases to ischemic stroke.
NADPH is a precursor reductant relative to GSH in that it is
used directly for reduction in GSSH to GSH by glutathione
reductase, and GSH can reduce ascorbate. However, GSH
and ascorbate can be immediately available through IV
administration, not requiring enzymatic transformation.
Additionally, ferric iron is reduced to ferrous in hemoglobin
by methemoglobin reductase, ascorbate and GSH, which
rescues hemoglobin for dioxygen binding, and a hallmark
of COVID-19 is problematic oxygen distribution. Proper
choice of chelator and performing sequential administration
of chelator then reductant may be important in preventing
initial ROS formation enhancement. Finally, a substantial
increase in the reductant levels may be necessary for
overwhelming, direct scavenging of ROS. Taken together,
clinically treating the redox/iron/ROS aspect of COVID-
19 in this manner is likely to be an important positive
contribution to the disease outcome and perhaps a dominant
contribution especially over some portion of disease
development timeframe.
It should be noted that the pharmacological options being
discussed herein are a combination of ideas stemming from in vitro
and in vivo research and thus are theoretical. They are put
forward here by a non-clinician and should only be considered in
that light. Furthermore, since the submission of this manuscript
3 months ago, publications addressing separate aspects of the
redox/iron/ROS triad have begun to appear in the literature. To
my knowledge, these reports do not treat redox, iron, and ROS
in a unified manner as is done in this perspective, nor do they
discuss many other details treated herein. These publications are
similar to occasional articles over the last decades suggesting
using reductants to treat various diseases.
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